Antidiabetic agents and dementia risk in type 2 diabetes: A systematic review and network meta‐analysis
The most effective antidiabetic agent in reducing dementia risk in T2DM is SGLT2i, followed by GLP1-RA, TZD and DPP4i, whereas insulin is associated with an elevated risk of dementia.
Authors
- Hiroshi Noto (ORCID: https://orcid.org/0000-0003-3591-7049)
- Masashi Tanaka (ORCID: https://orcid.org/0000-0003-0719-8972)
- Mitsuhiko Noda (ORCID: https://orcid.org/0000-0003-0413-4631)
- Noriko Satoh‐Asahara (ORCID: https://orcid.org/0000-0002-8645-3144)
- Takujiro Iuchi
- Ryo Suzuki (ORCID: https://orcid.org/0000-0002-2965-6906)
- Naoki Ozu (ORCID: https://orcid.org/0009-0004-8790-587X)
- Hajime Yamakage (ORCID: https://orcid.org/0000-0003-2783-6986)
- Hisashi Kato (ORCID: https://orcid.org/0000-0003-4395-8369)
- Michiaki Fukui (ORCID: https://orcid.org/0000-0003-0903-1797)
- Sayaka Kato (ORCID: https://orcid.org/0009-0007-1243-1114)
Institutions
- Tokyo Medical University (JP)
- Kyoto Medical Center (JP)
- Kyoto Prefectural University of Medicine (JP)
- St. Luke's International Hospital (JP)
- University of Yamanashi Hospital (JP)
- Nara Medical University Hospital (JP)
- Japanese Red Cross Society Kyoto Daini Hospital (JP)
- Furukawa Electric (Japan) (JP)
- National Center for Geriatrics and Gerontology (JP)
- University of Yamanashi (JP)
- International University of Health and Welfare (JP)
- Saitama Medical University (JP)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-10-22
- DOI
- https://doi.org/10.1111/dom.70182
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.29
Funders
- Japan Agency for Medical Research and Development